On November 28, 2016, the First Circuit upheld the dismissal of all but one of the class action securities fraud claims against Cambridge, MA drug company, ARIAD Pharmaceuticals, Inc., reaffirming the exacting pleading...more
12/1/2016
/ Class Action ,
Financial Markets ,
Food and Drug Administration (FDA) ,
Material Misstatements ,
Pharmaceutical Industry ,
Pleading Standards ,
Prescription Drugs ,
PSLRA ,
Rule 10(b) ,
Rule 10b-5 ,
Scienter ,
Section 11 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation ,
Stocks
Earlier this spring, in our post titled, The Supreme Court Ponders the Future of the Basic Presumption in Securities Litigation, we reported on the oral arguments before the Supreme Court in Halliburton Co. v. Erica P. John...more
The Supreme Court recently heard oral argument in Halliburton Co. v. Erika P. John Fund, Inc. in advance of what could be the most important decision affecting securities litigation in recent history. The outcome of the...more